Nicolas Castagneris

[Diego A. Díaz-García @diegoadiazg]

🫁 PD-L1 Negative NSCLC.

In a real-world cohort of 457 patients, nivolumab + ipilimumab + chemotherapy was associated with longer OS than pembrolizumab + chemotherapy in PD-L1 TPS <1% tumors:
• Median OS: 47.4 vs 16.6 months
• HR 0.50 (p=0.007)
No OS difference was observed in PD-L1 TPS ≥1%.

📖 Lung Cancer
DOI 👉🏻 https://t.co/I0ToWgihVK

#CánCare #NSCLC #lcsm #ThoracicOncology #Immunotherapy #PDL1

[Christian Rolfo @ChristianRolfo]

Our paper is online @JTOonline Molecular Profiling across 80,000 Patients with Lung Cancer. A robust demonstration that we need to test all patients with NSCLC &amp; ALL histologies and open the door for nomenclature change. https://t.co/eSoa62vtX3 @Al3ssandroRusso @OhioStateMedOnc

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

✅#ASCO25 DIA 2 Education Session
🇦🇷#AAOC #GAOT 🫁

🤔Dilema de la 1era LINEA en aNSCLC EGFRmut
Interesante discusión sobre eficacia, efectos adversos y toxicidad financiera

➡️OSI solo (FLAURA)
➡️OSI + QT (FLAURA2)
➡️AMI + LAZER (MARIPOSA)

@JuliaRotow @ACortelliniMD

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

CHICAGO 2025: ENCUENTRO EN EL CONSULADO ARGENTINO
https://t.co/ovUh8qCdId
La Asociación Argentina de Oncología Clínica participó de un encuentro promovido por el Consulado Argentino en Chicago, en el marco del Congreso Internacional de la Sociedad Americana de Oncología Clínica.

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

PRIMER SIMPOSIO AAOC-SATRO Tucumán 2025
Cáncer de Pulmón
Dres. Castagneris, Smith, Rodriguez Mignola, Berutti, Ferraris, Kaen, Martin

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

PRIMER SIMPOSIO AAOC-SATRO Tucumán 2025
El Dr. Claudio Martín, presidente de la AAOC (segundo de izq a der.), junto con los directores de la actividad, Dres Palazzo, Mendaña, Krakobsky, Castagneris

[Yakup Ergün @dr_yakupergun]

Updates on the treatment of epidermal growth factor receptor-mutant non–small cell lung cancer

Excellent review👇

https://t.co/2oPIEm2oSU

[Journal of Clinical Oncology @JCO_ASCO]

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Prior to Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer: https://t.co/bb8MlxhsRS

Authored by @ajuloorimd et al.

#NSCLC #lcsm

[Diego Enrico @DiegoEnricoMD]

✅ First report of our web mobile app📱 to assess Electronic Patient-Reported Outcomes (ePRO) and monitor patients in this case with advanced ALK+ NSCLC -ePROtector Study- 🔍 🇦🇷 #ELCC2025

Looking forward to expanding this initiative with many more colleagues and centers‼️

[Alessandra Dodi @alessandra_dodi]

What an honor to share at #ESMOImmuno24 our results suggesting that NSCLC with KRAS-nonG12C, BRAF-non600E, PIK3CA mutations show a better outcome and develop an activated circulating immunophenotype when treated with ICIs! Thanks @MarianaBrandao0 for the outstanding discussion!

[Elliot Servais, MD, FACS @ElliotServaisMD]

PROSPECT-Lung has opened

Perioperative chemoimmuno vs adjuvant only for stage IIA-IIIB resectable NSCLC

@SWOG

An important study, but does the community have equipoise for upfront surgery?

[Ferdinandos Skoulidis @FSkoulidis]

Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo. Thankful to our patients. @MDAndersonNews

[Stephen V Liu, MD @StephenVLiu]

Real world study of first-line nivolumab + ipilimumab for pleural #mesothelioma (ImmunoMeso LATAM) @ClinicalLung from @DiegoEnricoMD et al. In 96 pts, PFS 8m, OS 22m (23m epithelioid, 19m non-epithelioid). Grade 3-4 adverse events in 18.5%.

https://t.co/8Wy7uk7FDc

[Julien Mazieres @JulienMazieres]

ADRIATIC is the « new PACIFIC »
⚠️Be prepared for subgroups analysis and many time points in future meetings. Anyway, durvalumab works in LS-SCLC following RT-CT regardless of PCI and platinum regimen. #ESMO2024 @OncoAlert + @NEJM paper 👏

[Kai @bmassutis]

Overcoming Osimertinib single agent in EGFR mut+ at #WCLC24 #LCSM @OncoAlert

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

CONVENIO AAOC - GRUPO GAOT
La Asociación Argentina de Oncología Clínica y Grupo GAOT (tumores torácicos) firmaron los "Terminos y Condiciones del Acuerdo para el Sostenimiento de Actividades de Grupos Colaborativos" durante el Congreso de Estándares Terapéuticos 2024.

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨@OncoAlert Hot off the press.

Just published @JCO_ASCO

Results of phase 2 clinical trial (27 patients) of #Neoadjuvant #Osimertinib in stage I-IIIA #EGFRm non-small cell #LungCancer.

Study DID NOT meet primary endpoint

#MPR rate: 14.8%

👇🏼
https://t.co/nwQKcIJwoJ

[Dr. Iván R. González @Dr_Ivanoncologo]

An interesting review 🤓👉of Treatment Sequences in Advanced EGFR-Mutated #NSCLC🫁:

🎯TKIs have revolutionized the evolution of advanced NSCLC with common EGFR mutation.
🎯Tumor heterogeneity and acquired resistance mechanisms are inevitable limits.
🎯Recent treatment combinations show better outcomes in progression-free survival.
🎯These advances come with more serious side effects compared to the current standard.
🎯New therapeutic options open up possibilities for various treatment sequences.
🎯It is essential to consider the clinical and biological profile, as well as the patient's preferences.

✴️This review proposes an overview of published and future advances in EGFR-mutated NSCLC and a management algorithm that considers the different first-line options. @OncoAlert @LungSummit @CharuAggarwalMD @FordePatrick @MHuynhLe
https://t.co/uxeQFYvKxE

[Jonathan Spicer MD PhD @DoctorJSpicer]

I hope the @IASLC and #LCSM community will find our team’s work useful! It was amazing to collaborate and learn from such a great group. There’s no doubt that this will have to become a living document with the incredible pace of development for patients with resectable NSCLC! https://t.co/OQNGjNJdrD

[Sanjay Popat @DrSanjayPopat]

Superb work from @CharlesSwanton &amp; team, helping us to better understand who may need an “Osi+” frontline approach &amp;why.

But, many UK labs don’t test TP53 &amp; many do but won’t report it (!)

EGFR status is best interpreted knowing TP53 and RB1 status at baseline.